

- |                         |   |         |
|-------------------------|---|---------|
| 1. Record Nr.           | UNISANNIOGAG0049545   |         |
| Autore                  | Plutarchus  |         |
| Titolo                  | Vite parallele : letture scelte / Plutarco ; con introduzione e commento di Giuseppe Ammendola  |         |
| Pubbl/distr/stampa      | Napoli : A. Rondinella, 1963  |         |
| Descrizione fisica      | 177 p. ; 22 cm  |         |
| Disciplina              | 883   |         |
| Collocazione            | 43BIBLIOTECA883   | PLUT vi |
| Lingua di pubblicazione | Italiano  |         |
| Formato                 | Materiale a stampa  |         |
| Livello bibliografico   | Monografia  |         |
| Note generali           | Testo in greco.   |         |
| 2. Record Nr.           | UNINA9910139555703321   |         |
| Autore                  | Irving Peter <1970->  |         |
| Titolo                  | Clinical Dilemmas in Inflammatory Bowel Disease : New Challenges  |         |
| Pubbl/distr/stampa      | Hoboken, : Wiley, 2011  |         |
| ISBN                    | 1-283-24049-1<br>9786613240491<br>1-4443-4257-6<br>1-4443-4254-1  |         |
| Edizione                | [2nd ed.]   |         |
| Descrizione fisica      | 1 online resource (286 p.)  |         |
| Altri autori (Persone)  | SiegelCorey A<br>RamptonDavid<br>ShanahanFergus   |         |
| Disciplina              | 616.344   |         |
| Soggetti                | Clinical dilemmas<br>Inflammatory bowel diseases<br>Inflammatory Bowel Diseases<br>Inflammatory bowel diseases - Decision making<br>Inflammatory bowel diseases -- Decision making<br>Intestinal Diseases<br>Gastroenteritis<br>Gastrointestinal Diseases<br>Digestive System Diseases<br>Disease |         |

Medicine  
Health & Biological Sciences  
Gastroenterology

Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di contenuto	<p>Clinical Dilemmas in Inflammatory Bowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD-passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment</p> <p>8 Probiotics and synbiotics: panacea or placebo</p> <p>9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids</p> <p>17 Steroids in Crohn's disease: do the benefits outweigh the dangers? Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use?</p> <p>26 What is the role of biologics in UC? 27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions</p> <p>34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis? 35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease</p> <p>41 Does anti-TNF therapy increase the risk of complications of surgery?</p>
Sommario/riassunto	The second edition of Clinical Dilemmas in Inflammatory Bowel

Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking

---